Detalhe da pesquisa
1.
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
Blood
; 129(9): 1166-1176, 2017 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28049640
2.
KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.
Blood
; 126(25): 2720-3, 2015 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26500342
3.
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Leuk Lymphoma
; 52(11): 2139-47, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21718141